跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

C-907

Supelco

氯硝西泮标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C15H10ClN3O3
CAS号:
1622-61-3
分子量:
315.71
EC號碼:
200-659-6
MDL號碼:
MFCD00057746
分類程式碼代碼:
41116107
PubChem物質ID:
329775195
NACRES:
NA.24

等級

certified reference material

品質等級

300

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

−20°C

SMILES 字串

[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1

InChI

1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

InChI 密鑰

DGBIGWXXNGSACT-UHFFFAOYSA-N

基因資訊

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

以Klonopin和Rivotril作为商品名出售的氯硝西泮是一种有效的长效苯二氮卓类药物，具有抗焦虑、抗惊厥、肌肉松弛和催眠作用。氯硝西泮是用于治疗癫痫的处方药。这款认证的Snap-N-Spike®溶液适合通过GC/MS或LC/MS应用用于法医分析、临床毒理学、尿液药物测试或疼痛处方监控。

應用


  • 氯硝西泮研究用溶液：用于测定苯二氮卓类衍生物（包括氯硝西泮）离解常数的化学计量学方法研究表明，它起到了提高药物分析精度的关键作用。该方法增进了我们对氯硝西泮在各种条件下相互作用的理解，有助于其在科学研究和药物制剂中的应用 (Shayesteh et al., 2015）。

  • 用于科学研究的高纯度氯硝西泮液体：一项在混合溶剂中采用药物（包括氯硝西泮）溶解度预测模型的研究提供了关于其溶解度行为的重要见解。这些知识对于我们优化药物配方、提高药物制剂的生物利用度非常重要（Jouyban et al., 2011）。

  • 作为GABA受体激动剂氯硝西泮在实验室实验中的应用：对人血浆中多苯二氮卓类药物（multibenzodiazepine）测定的研究突出了氯硝西泮在临床和药物研究中的重要性，尤其是它影响GABA受体的作用，这对我们了解其药理学影响至关重要 (Borges et al., 2009）。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

产品编号
说明
价格

A-915

7-氨基氯硝西泮标准液 溶液, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-916

7-氨基氯硝西泮标准液 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-917

7-Aminoclonazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-924

7-Aminoclonazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-033

8种苯二氮卓类混标 CRM 溶液, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-905

Benzodiazepine Internal Standard-3 solution, 0.5-1.0 mg/mL in acetonitrile, ampule of 1.0 mL, certified reference material, Cerilliant®

C-905

氯硝安定-D4 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-906

氯硝安定-d4 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-047

氟溴唑仑 溶液, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-159

Diclazepam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

M-197

甲氯西泮 溶液, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

M-198

甲氯西泮-D3 溶液, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-160

2-氯地西泮-D4 溶液, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Raffaele Ferri et al.
Sleep medicine, 14(1), 24-29 (2012-10-27)
To analyze the differences in sleep structure and nocturnal motor activity between drug-free REM sleep behavior disorder (RBD) patients and those under therapy with clonazepam, and to evaluate the long-term longitudinal changes under continued therapy with clonazepam. Fifty-seven consecutive iRBD
Stuart J McCarter et al.
Sleep medicine, 14(3), 237-242 (2013-01-29)
REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin
Shigeru Morishita
Human psychopharmacology, 24(3), 191-198 (2009-03-31)
Clonazepam, first used for seizure disorders, is now increasingly used to treat affective disorders. We summarize the use of clonazepam to improve the management of depression. Clonazepam is useful for treatment-resistant and/or protracted depression, as well as for acceleration of
G Chouinard
The Journal of clinical psychiatry, 48 Suppl, 29-37 (1987-10-01)
This is a report on the efficacy of clonazepam in the treatment of acute mania. The advantages of clonazepam over standard neuroleptics are its rapidity of action, its lack of toxicity, and, particularly important, the fact that it does not
M L C Rodríguez et al.
Neuropharmacology, 64, 432-442 (2012-07-24)
A consolidated memory recalled by a specific reminder can become unstable (labile) and susceptible to facilitation or impairment for a discrete period of time. This labilization phase is followed by a process of stabilization called reconsolidation. The phenomenon has been
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门